Rate My Professor Harendra Parekh

Parekh's research specializations encompass pharmaceutical medicinal chemistry and pharmaceutics, with emphasis on innovative formulation and device co-development alongside advanced non-viral, bioresponsive drug and gene delivery systems. His group's developments include the Sol-Gel platform for direct nose-to-brain therapeutics delivery, a US-patented bioresponsive linker technology stabilizing peptide therapeutics, bioresponsive lipid nanoparticles featuring tissue targeting and gene catch-and-release functionality, and micro- and nanobubble formulations enabling ultrasound-mediated on-demand drug release, particularly for ocular applications. He has obtained significant funding through NHMRC Ideas Grants, ARC Training Centres, and other schemes. Notable publications comprise 'Development and characterisation of a thermoreversible sol–gel for intranasal delivery of MRI and PET imaging agents' (2026, International Journal of Pharmaceutics), 'Ameliorative anticancer effect of dendrimeric peptide modified liposomes of letrozole: in vitro and in vivo performance evaluations' (2023, International Journal of Pharmaceutics), 'Porous silicon embedded in a thermoresponsive hydrogel for intranasal delivery of lipophilic drugs to treat rhinosinusitis' (2023, Journal of Controlled Release), and 'A systematic review of ultrasound-mediated drug delivery to the eye and critical insights to facilitate a timely path to the clinic' (2023, Theranostics). As Scientific Founder and Chief Research Officer of PreveCeutical and BioGene Therapeutics, Parekh drives clinical translation of his platforms via industry collaborations.